

Oxford Project to Investigate Memory and Ageing (OPTIMA)

PUBLICATIONS BY MEMBERS OF OPTIMA 2008

Endpoints for trials in Alzheimer's disease: a European task force consensus.

Vellas,B.; Andrieu,S.; Sampaio,C.; Coley,N.; Wilcock,G.
Lancet Neurol 2008 7:436-50

A SNP in the ACT gene associated with astrocytosis and rapid cognitive decline in AD.

Belbin, O., Dunn, J. L., Chappell, S., Ritchie, A. E., Ling, Y., Morgan, L., Pritchard, A., Warden, D. R., Lendon, C. L., Lehmann, D. J., Mann, D. M., Smith, A. D., Kalsheker, N. and Morgan, K.
Neurobiol Aging, 2008: 29, 1167-1176.

Utility of the Malayalam translation of the 7- minute screen for Alzheimer's disease risk in an Indian community.

de Jager, C. A., Thambisetty, M., Praveen, K. V., Sheeba, P. D., Ajini, K. N., Sajeev, A., Smitha, K. K., Rahmathulla, L. P., Ramakrishna, T. and Smith, A. D. Neurol India, 2008: 56, 161-166.

Homocysteine and cognitive performance: modification by the ApoE genotype.

Elias, M. F., Robbins, M. A., Budge, M. M., Elias, P. K., Dore, G. A., Brennan, S. L., Johnston, C. and Nagy,Z.
Neurosci Lett, 2008: 430, 64-69.

Homocysteine, cysteine, and body composition in the Hordaland Homocysteine Study: does cysteine link amino acid and lipid metabolism?

Elshorbagy, A. K., Nurk, E., Gjesdal, C. G., Tell, G. S., Ueland, P. M., Nygard, O., Tverdal, A., Vollset, S. E. and Refsum, H. Am J Clin Nutr, 2008: 88, 738-746.

Folic acid fortification and cancer risk.

Mason, J. B., Cole, B. F., Baron, J. A., Kim, Y. I. and Smith, A. D.
Lancet, 2008: 371, 1335; author reply 1335-1336.

Are we ready for mandatory fortification with vitamin B-12?

Refsum, H. and Smith, A. D.
Am J Clin Nutr, 2008: 88, 253-254.

Is folic acid good for everyone?

Smith, A. D., Kim, Y. I. and Refsum, H.
Am J Clin Nutr, 2008: 87, 517-533

The worldwide challenge of the dementias: A role for B vitamins and homocysteine?

Smith, A. D. Food Nutr Bull, 2008: 29, S143-172.

Visual mismatch negativity highlights abnormal pre-attentive visual processing in mild cognitive impairment and Alzheimer's disease.

Tales, A., Haworth, J., Wilcock, G., Newton, P. and Butler, S.
Neuropsychologia, 2008: 46, 1224-1232.

Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients.

A. Tasker, C. G. Ballard, C. Joachim, D. R. Warden, E. J. Okello, R. H. Perry, N. Khan, A. D. Smith, D. J. Lehmann and E. K. Perry. Neurosci Lett, 2008. 442, 297-9

Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels.

Tunbridge, E. M., Harrison, P. J., Warden, D. R., Johnston, C., Refsum, H. and Smith, A. D.
Am J Med Genet B Neuropsychiatr Genet, 2008: 147B, 996-999.

Endpoints for trials in Alzheimer's disease: a European task force consensus.

Vellas, B., Andrieu, S., Sampaio, C., Coley, N. and Wilcock, G.
Lancet Neurol, 2008: 7, 436-450.

Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA study.

Visser, P. J., Verhey, F. R., Boada, M., Bullock, R., De Deyn, P. P., Frisoni, G. B., Frolich, L., Hampel, H., Jolles, J., Jones, R., Minthon, L., Nobili, F., Olde Rikkert, M., Ousset, P. J., Rigaud, A. S., Scheltens, P., Soininen, H., Spiru, L., Touchon, J., Tsolaki, M., Vellas, B., Wahlund, L. O., Wilcock, G. and Winblad, B.
Neuroepidemiology, 2008: 30, 254-265.

Vitamin B12 status and rate of brain volume loss in community-dwelling elderly.

Vogiatzoglou, A., Refsum, H., Johnston, C., Smith, S. M., Bradley, K. M., de Jager, C., Budge, M. M. and Smith, A. D.

Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.

Wilcock, G. K., Ballard, C. G., Cooper, J. A. and Loft, H.
J Clin Psychiatry, 2008: 69, 341-348.

Efficacy and safety of tarenfluril in mild to moderate Alzheimer's disease: a randomised phase II trial.

Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A. and Laughlin, M. A.
Lancet Neurol, 2008: 7, 483-493.

Safety and efficacy of galantamine in subjects with mild cognitive impairment.

Winblad, B., Gauthier, S., Scinto, L., Feldman, H., Wilcock, G. K., Truyen, L., Mayorga, A. J., Wang, D., Brashear, H. R., Nye, J. S. and The, G. A. L. I. N. T. S. G.
Neurology, 2008: 70, 2024-2035.

Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects.

Wu, G., Sankaranarayanan, S., Tugusheva, K., Kahana, J., Seabrook, G., Shi, X. P., King, E., Devanarayan, V., Cook, J. J. and Simon, A. J.
Clin Biochem, 2008: 41, 986-996.